ZyVersa Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • ZVSA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.49
  • (As of Friday Closing)

ZyVersa Therapeutics General Information

Description

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Contact Information

Website
www.zyversa.com
Formerly Known As
Variant Pharmaceuticals, Zyversa Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 2200 North Commerce Parkway
  • Suite 208
  • Weston, FL 33326
  • United States
+1 (754) 000-0000

ZyVersa Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ZyVersa Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.49 $4.86 $4.44 - $180.25 $3.41M 407K -$1.14K

ZyVersa Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 2,567 (65)
Revenue 0 0 0 0
EBITDA (105,978) (107,744) (13,610) (7,252)
Net Income (97,581) (98,298) (14,048) (8,084)
Total Assets 21,651 22,114 118,506 1,126
Total Debt 0 9 109 9,152
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ZyVersa Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ZyVersa Therapeutics‘s full profile, request access.

Request a free trial

ZyVersa Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop dr
Drug Discovery
Weston, FL
7 As of 2023
000.00
00000000 000.00

000000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut l
0000 000000000
Fitzroy, Australia
00 As of 0000
000.00
000000000 000.00

000000

trud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000 000000000
Encinitas, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ZyVersa Therapeutics Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dimerix Formerly VC-backed Fitzroy, Australia 00 000.00 000000000 000.00
Ventyx Biosciences Formerly VC-backed Encinitas, CA 00 00000 000000000 00000
Bionomics Formerly VC-backed Sydney, Australia 0 000.00 00000000 000.00
NodThera Venture Capital-Backed Boston, MA 00 00000 00000000000 00000
Adiso Therapeutics Venture Capital-Backed Concord, MA 00 00000 000000 0 00000
You’re viewing 5 of 31 competitors. Get the full list »

ZyVersa Therapeutics Patents

ZyVersa Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220175961-A1 Improved therapeutic method for rare ocular diseases by gene replacement Pending 08-Mar-2019 0000000000
EP-3935076-A1 Improved therapeutic method for rare ocular diseases by gene replacement Pending 08-Mar-2019 0000000000

ZyVersa Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Stephen Glover Co-Founder & Chief Executive Officer, President & Chairman
Peter Wolfe Chief Financial Officer
Karen Cashmere Chief Commercial Officer
Pablo Guzman MD Chief Medical Officer & Senior Vice President
You’re viewing 4 of 6 executive team members. Get the full list »

ZyVersa Therapeutics Board Members (14)

Name Representing Role Since
Gregory Freitag JD ZyVersa Therapeutics Board Member 000 0000
James Sapirstein Self Board Member 000 0000
Minchul Park Ph.D Self Board Member 000 0000
Robert Finizio Self Board Member 000 0000
Stephen Glover ZyVersa Therapeutics Co-Founder & Chief Executive Officer, President & Chairman 000 0000
You’re viewing 5 of 14 board members. Get the full list »

ZyVersa Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ZyVersa Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ZyVersa Therapeutics‘s full profile, request access.

Request a free trial

ZyVersa Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Larkspur Health Acquisition 12-Dec-2022 0000000000 00000 Special Purpose Acquisition Company (SPAC) 0000000 0
To view ZyVersa Therapeutics’s complete acquisitions history, request access »

ZyVersa Therapeutics FAQs

  • When was ZyVersa Therapeutics founded?

    ZyVersa Therapeutics was founded in 2014.

  • Who is the founder of ZyVersa Therapeutics?

    Stephen Glover is the founder of ZyVersa Therapeutics.

  • Who is the CEO of ZyVersa Therapeutics?

    Stephen Glover is the CEO of ZyVersa Therapeutics.

  • Where is ZyVersa Therapeutics headquartered?

    ZyVersa Therapeutics is headquartered in Weston, FL.

  • What is the size of ZyVersa Therapeutics?

    ZyVersa Therapeutics has 7 total employees.

  • What industry is ZyVersa Therapeutics in?

    ZyVersa Therapeutics’s primary industry is Drug Discovery.

  • Is ZyVersa Therapeutics a private or public company?

    ZyVersa Therapeutics is a Public company.

  • What is ZyVersa Therapeutics’s stock symbol?

    The ticker symbol for ZyVersa Therapeutics is ZVSA.

  • What is the current stock price of ZyVersa Therapeutics?

    As of 17-May-2024 the stock price of ZyVersa Therapeutics is $4.49.

  • What is the current market cap of ZyVersa Therapeutics?

    The current market capitalization of ZyVersa Therapeutics is $3.41M.

  • Who are ZyVersa Therapeutics’s competitors?

    Dimerix, Ventyx Biosciences, Bionomics, NodThera, and Adiso Therapeutics are some of the 31 competitors of ZyVersa Therapeutics.

  • What is ZyVersa Therapeutics’s annual earnings per share (EPS)?

    ZyVersa Therapeutics’s EPS for 12 months was -$1.14K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »